News

Contribution to the Personalized Healthcare for Melanoma
Approval for BRAF inhibitor, “Zelboraf^®” and its Companion Diagnostic, “cobas^® 4800 BRAF V600 Mutation Test.”

[PDF 119KB]

Chugai Wins the First Instance of the
Patent Infringement Lawsuit for Oxarol^® Ointment

[PDF 107KB]

Participation in the Global Health Innovative Technology Fund
(GHIT Fund)

[PDF 120KB]

Anti-Cancer Agent “Xeloda^®”
Application for Approval of Additional Indication of “Postoperative Adjuvant Chemotherapy for Gastric Cancer”

[PDF 123KB]

Complete Phase I Results of Chugai’s Bispecific Antibody "ACE910" Released at the American Society of Hematology Meeting

[PDF 155KB]

“INNOVATION BEYOND IMAGINATION”
Creating value beyond our conventional ideas and expectations

[PDF 237KB]

Personnel Changes

[PDF 140KB]

Phase I Data of Chugai’s Bispecific Antibody "ACE910" to be Presented at The American Society of Hematology Meeting

[PDF 93KB]

Supply Plan of "Tamiflu^®" Anti-influenza Drug for the 2014-2015 Season

[PDF 143KB]

Fulfilling the Philosophy of Para-Sports Aimed at “Increase of Vitality for Convivial Society”

[PDF 113KB]

F. Hoffmann-La Roche Announces Third Quarter Sales 2014

[PDF 76KB]

Chugai to Join “BioJapan2014” as an Official Sponsor
The Largest Biotechnology Partnering Event in Asia

[PDF 340KB]

Chugai Receives Two Awards in
“Commendation of Companies Promoting Gender Equality and Work-Family Balance 2014”
Hosted by the Ministry of Health, Labour and Welfare

[PDF 217KB]

Bisphosphonate Antiresorptive Agent,
Ibandronate Sodium Hydrate Oral Agent,
Demonstrates Efficacy in Osteoporosis in Phase III Trial

[PDF 21KB]

Chugai Debuts on Dow Jones Sustainability Asia Pacific Index,
an Index for Socially Responsible Investment

[PDF 189KB]

Roche’s RoACTEMRA Receives EU Approval for Use in Patients
with Early Rheumatoid Arthritis (RA)

[PDF 237KB]

30^th Contribution of Para-transit Vehicles to Welfare Services
A Total of 203 Vehicles will be Donated

[PDF 224KB]

Launch of the Anti-Cancer Agent / ALK Inhibitor “Alecensa^®”

[PDF 199KB]

Results of Japanese Phase II Clinical Trial for
Non-Small Cell Lung Cancer with EGFR Mutations was
Published Online on “The Lancet Oncology”

[PDF 181KB]

Amendment of Business Arrangements Regarding
the Conditions for Out-Licensing Chugai Products
Based on the Strategic Alliance between Chugai and Roche

[PDF 178KB]

Disclosure of Information on Chugai’s 2013 Corporate Activities
Based on Transparency Guidelines

[PDF 176KB]

Regarding a Certain Media Report

[PDF 16KB]

Organizational and Personnel Changes

[PDF 200KB]

F. Hoffmann-La Roche Announces Half Year Results 2014

[PDF 21KB]

Helsinn Group and Chugai Pharma Marketing Enter into Agreement for
Marketing Rights of Netupitant-Palonosetron Fixed-Dose Combination
(NEPA) in The UK and Ireland and for Palonosetron Monotherapy in The UK

[PDF 54KB]

PharmaMar and Chugai Pharma Marketing Enter into a License and
Commercialization Agreement in Europe for Aplidin^®

[PDF 58KB]

An Anti-Cancer Agent, ALK Inhibitor “Alecensa^®,”
Approved for the Treatment of ALK Fusion Gene Positive
Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer

[PDF 183KB]

“Along with Antibody Drugs” — A Movie Newly Posted on Chugai’s
Website, Including Easy-to-understand Information on Antibody
Engineering Technologies as Chugai’s Strength

[PDF 311KB]

Chugai Offers Biology Laboratory Class
for Elementary School Students

[PDF 234KB]

Chugai and Roche Enter a License Agreement for
Chugai’s Proprietary Innovative Antibody Engineering Technologies

[PDF 207KB]

Determination of Terms and Conditions of Stock Options
(Stock Acquisition Rights)

[PDF 36KB]

Roche Receives EU Approval for New Subcutaneous
Formulation of RoACTEMRA
Providing more Treatment Flexibility
for Patients with Moderate to Severe Rheumatoid Arthritis

[PDF 200KB]

Chugai Pharma USA Announces Appointment of
Chief Medical Officer

[PDF 180KB]

Issuance of Stock Options (Stock Acquisition Rights)

[PDF 76KB]

Launch of the Anti-Cancer Agent “Kadcyla^®”

[PDF 214KB]

F. Hoffmann-La Roche Announces First Quarter Sales 2014

[PDF 21KB]

New Drug Application Filed for “Vemurafenib”
for the Treatment of Melanoma with BRAF^V600 Mutation
and a Companion Diagnostic to Detect the BRAF Mutation

[PDF 64KB]

Chugai to Participate in
High-Quality Protein Crystal Growth Experiment
in the International Space Station, “Kibo,” as Private Company

[PDF 214KB]

Chugai Won the Award for Excellence
in the 16th Nikkei Annual Report Awards

[PDF 190KB]

Personnel Changes

[PDF 130KB]

F. Hoffmann-La Roche Announces Financial Results for Fiscal 2013

[PDF 45KB]